Validation of the Medical Research Council sum score (MRCss) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy

IF 3.2 4区医学 Q2 CLINICAL NEUROLOGY

Journal of neuromuscular diseases Pub Date : 2023-03-27 DOI:10.17650/2222-8721-2023-13-1-68-74

N. Suponeva, A. S. Arestova, E. Melnik, A. Zimin, A. Zaytsev, A. Yakubu, E. S. Sherbakova, D. G. Yusupova, D. Grishina, E. Gnedovskaya, M. Piradov

{"title":"Validation of the Medical Research Council sum score (MRCss) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy","authors":"N. Suponeva, A. S. Arestova, E. Melnik, A. Zimin, A. Zaytsev, A. Yakubu, E. S. Sherbakova, D. G. Yusupova, D. Grishina, E. Gnedovskaya, M. Piradov","doi":"10.17650/2222-8721-2023-13-1-68-74","DOIUrl":null,"url":null,"abstract":"Background. The use of rating scales and questionnaires is essential in an evaluation of disease course, treatment response, the disability level and quality of life in patients with chronic inflammatory demyelinating polyneuropathy. The Medical Research Council (MRC) scale and its modification Medical Research Council sum score (MRCss) are widely used for measurement of motor deficit in patients with neuromuscular disorders. However, its usage is limited by the absence of the validated version for Russian-speaking patients.Aim. To validate MRCss scale in patients with chronic inflammatory demyelinating polyneuropathy with development of a Russian version.Materials and methods. We enrolled 50 patients with chronic inflammatory demyelinating polyneuropathy (25 with typical chronic inflammatory demyelinating polyneuropathy and 25 with Lewis–Sumner syndrome). At the first step we conducted linguocultural ratification according to the standard protocol. At the second step the psychometric parameters were evaluated, such as reliability, validity and sensitivity.Results. The developed Russian version of MRCss scale demonstrated the high level of reliability, validity and sensitivity.Conclusion. As a result, we developed a validated Russian version of MRCss scale, recommended for clinical practice and research. ","PeriodicalId":16536,"journal":{"name":"Journal of neuromuscular diseases","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2023-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuromuscular diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17650/2222-8721-2023-13-1-68-74","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background. The use of rating scales and questionnaires is essential in an evaluation of disease course, treatment response, the disability level and quality of life in patients with chronic inflammatory demyelinating polyneuropathy. The Medical Research Council (MRC) scale and its modification Medical Research Council sum score (MRCss) are widely used for measurement of motor deficit in patients with neuromuscular disorders. However, its usage is limited by the absence of the validated version for Russian-speaking patients.Aim. To validate MRCss scale in patients with chronic inflammatory demyelinating polyneuropathy with development of a Russian version.Materials and methods. We enrolled 50 patients with chronic inflammatory demyelinating polyneuropathy (25 with typical chronic inflammatory demyelinating polyneuropathy and 25 with Lewis–Sumner syndrome). At the first step we conducted linguocultural ratification according to the standard protocol. At the second step the psychometric parameters were evaluated, such as reliability, validity and sensitivity.Results. The developed Russian version of MRCss scale demonstrated the high level of reliability, validity and sensitivity.Conclusion. As a result, we developed a validated Russian version of MRCss scale, recommended for clinical practice and research.

查看原文本刊更多论文

医学研究委员会总评分(MRCss)用于俄语慢性炎症性脱髓鞘性多神经病变患者的验证

背景。在评估慢性炎症性脱髓鞘性多神经病变患者的病程、治疗反应、残疾水平和生活质量时，使用评分量表和问卷是必不可少的。医学研究委员会(MRC)量表及其修正版医学研究委员会总评分(MRCss)被广泛用于测量神经肌肉疾病患者的运动缺陷。然而，由于缺乏针对俄语患者的有效版本，它的使用受到了限制。验证MRCss量表在慢性炎症性脱髓鞘多神经病变患者中的应用，并开发俄罗斯版本。材料和方法。我们招募了50例慢性炎性脱髓鞘性多神经病变患者(25例为典型慢性炎性脱髓鞘性多神经病变，25例为Lewis-Sumner综合征)。在第一步，我们根据标准议定书进行了语言批准。第二步，对心理测量参数进行信度、效度和灵敏度评估。研制的俄文MRCss量表具有较高的信度、效度和敏感性。因此，我们开发了一个经过验证的俄罗斯版本的MRCss量表，推荐用于临床实践和研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neuromuscular diseases Medicine-Neurology (clinical)

CiteScore

5.10

自引率

6.10%

发文量

102

期刊介绍： The Journal of Neuromuscular Diseases aims to facilitate progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias and myositis). The journal publishes research reports, reviews, short communications, letters-to-the-editor, and will consider research that has negative findings. The journal is dedicated to providing an open forum for original research in basic science, translational and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases.